Alternative concepts of suicide gene therapy for graft-versus-host disease after adoptive immunotherapy

Acta Haematologica

Volumn 110, Issue 2-3, 2003, Pages 132-138

  Kramm, Christof M ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Donor lymphocytes; Gene therapy; Graft versus host disease; Leukemia; Suicide gene

Indexed keywords

ACICLOVIR; AP 1903; CYTARABINE; GANCICLOVIR; IRINOTECAN; METHOTREXATE; PRODRUG; RECOMBINANT ENZYME; RITUXIMAB; TACROLIMUS; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS ENZYME;

ACUTE LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; BONE MARROW TOXICITY; DNA MODIFICATION; DRUG BINDING; DRUG EFFECT; DRUG SAFETY; GENE INACTIVATION; GENE THERAPY; GENETIC MARKER; GENETIC SELECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MALIGNANT TRANSFORMATION; NONHODGKIN LYMPHOMA; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SIGNAL TRANSDUCTION; SUICIDE GENE; T CELL LEUKEMIA; T LYMPHOCYTE; TREATMENT OUTCOME;

ADOPTIVE TRANSFER; GENES, TRANSGENIC, SUICIDE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA; LYMPHOCYTES;

EID: 0242299674     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072462     Document Type: Review

References (36)

1. Adachi M, Sampath J, Lan LB, Sun D, Hargrove P, Flatley R, Tatum A, Edwards MZ, Wezeman M, Matherly L, Drake R, Schuetz J: Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. J Biol Chem 2002;277:38998-39004.
2. Aghi M, Hochberg F, Breakefield XO: Prodrug activation enzymes in cancer gene therapy. J Gene Med 2000;2:148-164.
3. Aghi M, Kramm CM, Breakefield XO: Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. J Natl Cancer Inst 1999;91:1233-1241.
4. Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA: Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/ cytosine deaminase gene therapies. J Natl Cancer Inst 1998;90:370-380.
5. Bader P, Klingebiel T, Schaudt A, Handgretinger R, Theurer-Mainka U, Lang P, Niethammer D, Beck J: Early immunotherapy after allogeneic SCT on the basis of increasing mixed chimerism in patients with acute leukemias can prevent frank hematological relapse: A single-center experience of 12 children. Leukemia 1999;13:2079-2086.
6. Beck JF, Klingebiel T, Kreyenberg H, Schaudt A, Hölle W, Niethammer D, Bader P: Rezidivprophylaxe bei Kindern mit ALL, AML und MDS nach allogener Stammzelltransplantation durch interventionelle Immuntherapie im kritischen Stadium eines ansteigenden gemischten Chimärismus. Klin Pädiatr 2002;214:201-205.
7. Bonini C, Bordignon C: Potential and limitations of HSV-TK-transduced donor peripheral blood lymphocytes after allo-BMT. Hematol Cell Ther 1997;39:273-274.
8. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719-1724.
9. Bordignon C, Bonini C, Verzeletti S, Nobili N, Maggioni D, Traversari C, Giavazzi R, Servida P, Zappone E, Benazzi E, et al: Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther 1995;6:813-819.
10. Cazzaniga S, Cavalieri S, Geuna M, Zulma M, Bordignon C, Bonini C, Naldini L: Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact repertoire. Mol Ther 2002;5:S166, abstr 505.
11. Chalmers D, Ferrand C, Apperley JF, Melo JV, Ebeling S, Newton I, Duperrier A, Hagenbeek A, Garrett E, Tiberghien P, Garin M: Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene. Mol Ther 2001;4:146-148.
12. Collins RH Jr, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, Barrett J, Johnson M, Kirk A, Horowitz M, Parker P: Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000;26:511-516.
13. Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-444.
14. Di Ianni M, Di Florio S, Venditti G, Liberatore C, Lucheroni F, Falzetti F, Terenzi A, Stella CC, Spinozzi F, Mannoni P, Martelli MF, Tabilio A: T-lymphocyte function after retroviral-mediated thymidine kinase gene transfer and G418 selection. Cancer Gene Ther 2000;7:920-926.
15. Duarte RF, Chen FE, Lowdell MW, Potter MN, Lamana ML, Prentice HG, Madrigal JA: Functional impairment of human T-lymphocytes following PHA-induced expansion and retroviral transduction: Implications for gene therapy. Gene Ther 2002;9:1359-1368.
16. Fehse B, Kustikova OS, Li Z, Wahlers A, Bohn W, Beyer WR, Chalmers D, Tiberghien P, Kuhlcke K, Zander AR, Baum C: A novel 'sort-suicide' fusion gene vector for T cell manipulation. Gene Ther 2002a;9:1633-1638.
17. Fehse B, Schade UM, Li Z, Uhde A, Koch S, Goller B, Ruger R, Fehse N, Stockschlader M, Zander AR: Highly efficient gene transfer with retroviral vectors into human T lymphocytes on fibronectin. Br J Haematol 1998;102:566-574.
18. 450 4B1 enzyme gene by two different prodrugs: Implications for pharmacogene therapy. Cancer Gene Ther 2002;9:178-188.
19. Garin MI, Garrett E, Tiberghien P, Apperley JF, Chalmers D, Melo JV, Ferrand C: Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 2001;97:122-129.
20. Hapke DM, Stegmann AP, Mitchell BS: Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res 1996;56:2343-2347
21. Hiller C, Wittmann S, Slavin S, Fickenscher H: Functional long-term thymidine kinase suicide gene expression in human T cells using a herpesvirus saimiri vector. Gene Ther 2000;7:664-674.
22. Introna M, Barbui AM, Bambacioni F, Casati C, Gaipa G, Borleri G, Bernasconi S, Barbui T, Golay J, Biondi A, Rambaldi A: Genetic modification of human T cells with CD20: A strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther 2000;11:611-120.
23. Introna M, Manganini M, Bonamino M, Broady R, Biondi A, Rambaldi A, Serafini M: Preclinical development of the CD20 suicide gene system in T and NK cells. 44th Annual Meeting of the American Society of Hematology, Philadelphia, Dec 6-10, 2002, abstr 2558.
24. Kojima A, Hackett NR, Ohwada A, Crystal RG: In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest 1998;101:1789-1796.
25. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041-2050.
26. Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J, Forster M, Stocking C, Wahlers A, Frank O, Ostertag W, Kuhlcke K, Eckert HG, Fehse B, Baum C: Murine leukemia induced by retroviral gene marking. Science 2002;296:497.
27. Litvinova E, Maury S, Boyer O, Bruel S, Benard L, Boisserie G, Klatzmann D, Cohen JL: Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease. Blood 2002;100:2020-2025.
28. Liu S, Song L, Bevins R, Birhiray O, Moscow JA: The murine-reduced folate carrier gene can act as a selectable marker and a suicide gene in hematopoietic cells in vivo. Hum Gene Ther 2002;13:1777-1782.
29. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
30. Moscow JA, Gong M, He R, Sgagias MK, Dixon KH, Anzick SL, Meltzer PS, Cowan KH: Isolation of a gene encoding a human-reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res 1995;55:3790-3794.
31. Porter DL, Roth MS, Lee SJ, McGarigle C, Ferrara JML, Antin JH: Adoptive immunotherapy with donor mononuclear cell in fusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996;18:975-980.
32. Sauce D, Bodinier M, Garin M, Petracca B, Tonnelier N, Duperrier A, Melo JV, Apperley JF, Ferrand C, Herve P, Lang F, Tiberghien P, Robinet E: Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood 2002;99:1165-1173.
33. Thomis DC, Marktel S, Bonini C, Traversari C, Gilman M, Bordignon C, Clackson T: A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 2001;97:1249-1257.
34. Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E, Certoux JM, Robinet E, Saas P, Petracca B, Juttner C, Reynolds CW, Longo DL, Herve P, Cahn JY: Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 2001;97:63-72.
35. Tomicic MT, Thust R, Sobol RW, Kaina B: DNA polymerase β mediates protection of mammalian cells against ganciclovir-induced cytotoxicity and DNA breakage. Cancer Res 2001;61:7399-7403.
36. Verzeletti S, Bonini C, Marktel S, Nobili N, Ciceri F, Traversari C, Bordignon C: Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: Clinical follow-up and improved new vectors. Hum Gene Ther 1998;9:2243-2251.